Immunic Inc
IMUX
Get informed when a big investor buys or sells
+ FollowMarket Cap$190.29M
Close$
$9.51
32.3% downside
Current Fair Value
32.3% downsideOvervalued by 32.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $190.29 Million |
|---|---|
| Enterprise Value | $4.08 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.24 |
| Beta | 1.38 |
| Outstanding Shares | 3,013,632 |
Return
| Return on Equity | -68.96% |
|---|---|
| Return on Assets | -54.96% |
| Return on Invested Capital | -69.32% |
Valuation & Multiples
| P/E Ratio | -2.34 |
|---|---|
| PEG | -8.36 |
| Price to Sales | - |
| Price to Book Ratio | 0.28 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.04 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 21, 2026
EPS Estimate
$-0.71
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-1.16
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2217▼ 2.62% |
|---|---|
| Total Calls | 302,700▲ 85.25% |
| Total Puts | 67,100▲ 65.68% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 21.22%▼ 5.22% |
|---|---|
| Total Invested | $71.00M▲ 151.26% |
| Investors Holding | 80▲ 17.00% |
ESG Score
No data
About Immunic Inc
28 employees
CEO: Daniel Vitt Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerati...